Human prothrombin complex - CSL Behring

Drug Profile

Human prothrombin complex - CSL Behring

Alternative Names: 4-factor PCC; 4-factor prothrombin complex concentrate; BE 1116; Beriplex; Beriplex P/N; Confidex; Kcentra

Latest Information Update: 12 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CSL Behring
  • Class Blood coagulation factors
  • Mechanism of Action Blood coagulation factor replacements; Factor IX stimulants; Factor VII stimulants; Factor X stimulants; Protein C inhibitors; Prothrombin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haemorrhage
  • New Molecular Entity No

Highest Development Phases

  • Marketed Haemorrhage

Most Recent Events

  • 30 Sep 2017 Launched for Haemorrhage in Japan (IV)
  • 30 Mar 2017 Registered for Haemorrhage in Japan (IV)
  • 01 Mar 2016 CSL Behring completes a phase IIIb trial for Haemorrhage in Japan (NCT02281201)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top